Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 8, 2020.
Welcome to NeurologyLive
's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive
's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Jeremy Payne, MD, PhD: The Lack of Progress for Telestroke
The director of the Stroke Center at Banner-University Medicine Neuroscience Institute spoke to the need for data like that from the TELECAST study and how the COVID-19 pandemic might push telestroke care forward.
2: Peer Exchange: Final Thoughts on Treating Narcolepsy
Michael J. Thorpy, MD; Russell Rosenberg, PhD, DABSM; Kiran Maski, MD, MPH; Alon Avidan, MD, MPH; and Eveline Honig, MD, MPH, wrap up their discussion by offering final thoughts and guidance on diagnosing and treating patients with narcolepsy.
3: Rituximab May Be More Effective in Early-Onset Myasthenia Gravis
This retrospective cohort study suggests that rituximab is more effective than conventional immunotherapy and might most impactful if initiated within 12 months of symptom onset in myasthenia gravis.
4: Peer Exchange: AL and ATTR Diagnosis: Echo and Noncardiac Biopsy
John L Berk, MD; Akshay Desai, MD, MPH; Mazen Hanna, MD; and Ronald Witteles, MD, discuss the subtle diagnosis of immunoglobulin light chain amyloidosis and transthyretin amyloidosis, with consideration for echocardiogram features and noncardiac biopsy.
5: Flortaucipir PET Tracer Accurately Supports Alzheimer Disease Pathology
The positron emission tomography tau tracer was shown to identify high levels of Alzheimer disease neuropathologic change and neurofibrillary tangles with good sensitivity and specificity.